Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
The initial consolidation of 株式会社ワイズマン, growth in support for digital transformation in healthcare settings, new contracts for CS sets, the foreign exchange impact of the weaker yen overseas, and an improved revenue mix contributed to higher revenue and profit. These factors were offset by the reaction to highly profitable projects in the same period of the previous year, lower unit prices following the revision of medical service fees, and increased upfront investment expenses for new openings, which restrained profit.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥181,853 million (YoY +6.4%) |
| Operating profit | ¥36,335 million (YoY +1.0%) |
| Ordinary income | ¥36,620 million (YoY -0.2%) |
| Profit attributable to owners of the parent | ¥19,997 million (YoY -11.9%) |
| Net income per share | ¥29.98 |
| Equity ratio | End of the current fiscal period 61.8% / End of previous period 64.0% |
| Total assets | ¥658,406 million |
| Net assets | ¥445,262 million |
| Cash and cash equivalents at end of period | ¥146,352 million |
| Full-year earnings forecast | Net Sales ¥400,000 million (YoY +13.8%) / Operating profit ¥80,000 million (YoY +8.8%) / Ordinary income ¥81,000 million (YoY +6.2%) / Net income ¥56,000 million (YoY +3.6%) / Profit for the period attributable to owners of the parent ¥53,000 million (YoY +7.9%) |
| Revision to Earnings Forecast | No |
| Annual Dividend Forecast | ¥22 → To be determined |
| Segment revenue | Medical Platform ¥54,384 million (YoY +4.6%), Evidence Solutions ¥11,713 million (YoY -3.8%), Career Solutions ¥12,686 million (YoY -3.7%), Site Solutions ¥28,735 million (YoY +9.3%), Patient Solutions ¥30,229 million (YoY +10.5%), Overseas ¥45,447 million (YoY +10.7%) |
| Segment profit | Medical Platform ¥18,487 million (YoY +3.5%), Evidence Solutions ¥1,973 million (YoY -15.3%), Career Solutions ¥4,438 million (YoY +2.2%), Site Solutions ¥930 million (YoY -45.1%), Patient Solutions ¥2,011 million (YoY +90.7%), Overseas ¥9,854 million (YoY +10.4%) |
| Depreciation and amortization | ¥9,799 million |
| Impairment loss | Reversal of impairment losses recognized (対象資産・金額は Not disclosed) |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | No material change. The report states that 株式会社ワイズマン became a subsidiary in July 2026 and was newly consolidated (1 new company). |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for analysts and institutional investors) |
| Issued Shares at Period-End | 679,128,200 Shares |
| Treasury Shares at Period-End | 13,671,139 Shares |
| Factors Behind Changes in Business Performance | The initial consolidation of 株式会社ワイズマン, growth in support for digital transformation in healthcare settings, new contracts for CS sets, the foreign exchange impact of the weaker yen overseas, and an improved revenue mix contributed to higher revenue and profit. These factors were offset by the reaction to highly profitable projects in the same period of the previous year, lower unit prices following the revision of medical service fees, and increased upfront investment expenses for new openings, which restrained profit. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The initial consolidation of 株式会社ワイズマン, growth in support for digital transformation in healthcare settings, the foreign exchange impact of the weaker yen overseas, and an improved revenue mix contributed to higher revenue and profit. These factors were offset by the reaction to highly profitable projects in the same period of the previous year, lower unit prices following the revision of medical service fees, and increased upfront investment expenses for new openings, which restrained profit.